SCHEMBL3369169

SCHEMBL3369169

COc1cccc(-c2nc(-c3ccccc3)nc(N)c2C#N)c1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 11/20 0.71
ADORA2A P29274 10/20 0.71
ADORA2B P29275 3/20 0.71
HSD17B10 Q99714 1/20 0.68
DPP4 P27487 1/20 0.66
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
LMNA P02545 1/20 0.63
RXFP1 Q9HBX9 3/20 0.59
MAPT P10636 1/20 0.59
HPGD P15428 3/20 0.58
HTT P42858 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
TP53 P04637 1/20 0.57
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 3/20 0.54
GLA P06280 1/20 0.53
ADORA3 P0DMS8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18893664 0.87 ADORA2A (0.64) ADORA1ADORA2AADORA2BHSD17B10DPP4
SCHEMBL5744860 0.86 ADORA1 (0.60) ADORA1ADORA2AADORA2BHSD17B10DPP4
SCHEMBL5740799 0.86 ADORA1 (0.60) ADORA1ADORA2AADORA2BHSD17B10DPP4
SCHEMBL3369377 0.83 ADORA2A (0.74) ADORA1ADORA2AADORA2BHSD17B10DPP4
SCHEMBL15286448 0.82 ADORA1 (0.67) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL15286427 0.82 ADORA1 (0.67) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL18893661 0.81 RXFP1 (0.67) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL3372051 0.80 DPP4 (0.70) ADORA1ADORA2AADORA2BHSD17B10DPP4
SCHEMBL18893675 0.80 ADORA1 (0.60) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL3368583 0.80 DPP4 (1.00) ADORA1ADORA2ADPP4ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 ADORA1 134/4885ADORA2A 794/4885ADORA2B 676/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK ADORA1 207/4885ADORA2A 547/4885ADORA2B 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.